BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 25, 2005--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced that it will release 2005 third quarter financial results on Tuesday, November 8, after the market close. At 4:30 P.M. ET, management will host a conference call to provide a company update, including a review of the progress with TOCOSOL(R) Paclitaxel, Sonus’ lead anti-cancer product. The Company recently announced the signing of a licensing agreement with Schering AG for the development and commercialization of TOCOSOL Paclitaxel. TOCOSOL Paclitaxel has shown promising safety and anti-tumor activity in Phase 2 clinical trials in a variety of solid tumors, and the product is currently in a Phase 3 pivotal study for the potential treatment of metastatic breast cancer.
